Clinical Trials Browser

Phase 1/2 × Lymphoma × Transplantation Conditioning × Clear all

NCT02053545 2019-08-30

Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma